Widespread interest in Nordic cooperation on clinical studies
The number of clinical studies being conducted in the Nordic countries has declined dramatically in recent years. Many clinical studies are instead being carried out in other countries, where costs are lower and there is a far larger patient base available compared to the Nordic countries. This may have potentially negative consequences for the Nordic countries’ international position in medical research, and could also lead to a situation in which Nordic country patients are no longer guaranteed access to the latest treatment methods. Fortunately, this trend can be reversed, believes project manager Pierre Lafolie of Karolinska University Hospital in Stockholm.
“The Nordic countries are not taking full advantage of their potential for multi-centre clinical trials,” asserts Dr Lafolie. “Clinical studies require large patient groups, which can be difficult to obtain at a national level. With roughly 26 million people, the Nordic countries can offer a competitive population base for clinical studies – as well as very high-quality biobanks and health registries and stable patient populations. The Nordic countries also have similar regulatory frameworks, and public confidence in the health care systems is high.”
The Nordic Trial Alliance was established to counter the decreasing trend in clinical studies. The initiative’s main objectives are to strengthen Nordic collaboration in this sphere by disseminating information and refining existing initiatives on clinical research, as well as to generate greater interest in these studies in political spheres and the research community alike.
A welcome initiative
There is a great need for Nordic cooperation on clinical studies, and the more than 90 conference participants considered the Nordic Trial Alliance to be an important first step. The conference focused on gauging the interest in Nordic cooperation on multi-centre clinical trials, and finding out what the research community thinks such cooperation should prioritise. Following the plenum presentations, which provided general information on the Nordic Trial Alliance and perspectives from academia and industry, participants split up into working groups to discuss different aspects of Nordic cooperation on multi-centre clinical trials. The working groups agreed it was important to act quickly to launch specific measures and projects, recommending that the Nordic Trial Alliance should establish a website with relevant scientific content as soon as possible. It would also be beneficial for the Nordic Trial Alliance to promote harmonisation of regulations and application processes among the Nordic countries, and to take action to spread information about the importance of Nordic multi-centre clinical trials to politicians, decision-makers and patient organisations.
The conference laid the foundation for closer cooperation in the Nordic countries, and project manager Lafolie was pleased with the outcome, saying, “We got the response we had hoped for. We have received lots of good input, and we will continue the close dialogue with the various interested parties. We will incorporate this input into a strategy for how to work most productively within the Nordic Trial Alliance.”
Text and photo: Marius Hagen